Interestingly, by referring to known drug targets of Food and Drug Administration (FDA)-approved drugs or candidate drugs in clinical trials, we identified 22 clinically actionable cell–matrix proteins, such as COL3A1, FGA, and ITGA5, whose expression was negatively correlated with the Mg content in tumors (Spearman’s rank correlation test, P < 0.05) (Figure S8; Table S8), suggesting that Mg might serve as an adjuvant drug for precise CRC treatment by affecting the levels of these potential drug targets. The gene discussed is PROS1; the disease is colorectal carcinoma.